News | August 02, 2011

PET Census: Slower But Continued Growth in PET Patient Studies (2008 to 2010)

August 2, 2011 – An estimated 1.7 million clinical positron emission tomography (PET) patient studies were performed in the United States in 2010, according to a report just released by IMV Medical Information Division. These PET studies were performed in 2,085 hospital and non-hospital sites, using fixed or mobile PET/computed tomography (CT) or PET scanners.

“The estimated 1,744,000 clinical PET patient studies performed in 2010 represent a 14.7 percent increase over IMV’s estimate of 1,520,800 patient studies performed in 2008, for an average annual growth rate of 7.1 percent over the two years,” said Lorna Young, senior director of market research at IMV. “This represents a slowing in the annual growth rate for PET patient studies, as the average annual rate between 2005 and 2008 was 10.4 percent. However, the annual 7 percent rate for procedures is still a significant growth rate, in an era of increased scrutiny of third-party insurers in their pre-authorization processes.”

Currently, PET technology is utilized primarily for oncology applications, which comprise 95 percent of the PET studies. Neurology and cardiology applications make up the remaining 5 percent, which are likely to become a larger proportion of the studies to be performed, as other radiopharmaceutical tracers, such as PET agents for Alzheimer’s, become approved for clinical use.

“In parallel with the continued evolution of the clinical utility of PET, the number of sites using fixed PET technology is increasing access to PET imaging. Although the number of sites performing PET imaging using fixed or mobile PET increased only 4 percent from 2,000 sites in 2008 to the current 2,085 sites, the mix of sites using fixed units versus mobile PET services has dramatically shifted. Over half of the sites, 1,150 sites, now use fixed PET imaging units, compared to one-third of the sites that were doing PET imaging back in 2003. With this increased access, the median waiting time for a scheduled outpatient appointment at sites using fixed or mobile PET or PET/CT scanners is four days, down from seven days in 2001,” Young said.

“Also, we see a sizable shift in sites using fixed PET/CTs compared to fixed PET scanners. When PET/CT came into the market around 2003, it was adopted rapidly, due to its unparalleled capability to image both anatomical structures and metabolic activity. In 2003, one-third of the installed base was PET/CT scanners, but now, about 90 percent of the fixed units are PET/CTs,” Young said.

“The market for PET scanners was affected by the general economic downturn in 2008. That, coupled with the near-completion of the replacement of the PET-only scanners with PET/CTs, may result in a slow recovery for unit sales. However, about 45 percent of the PET imaging sites currently use mobile services, and they may purchase their first fixed unit as they grow their volume and referrals. Newly introduced technology such as PET/magnetic resonance (MR) may stimulate the demand for additional units in the larger PET centers. Over the next few years, about half of the PET scanner demand will come from first buyers, who are primarily mobile users, about one-third will be replacement buyers and the remaining purchases will be for additional units.”

The report describes trends in PET and PET/CT patient studies by procedure type, PET and PET/CT installed base by manufacturer and year of installation, planned purchases and market scenarios for unit sales through 2015, radiopharmaceutical utilization and expenditures by supplier, and site operations characteristics. Other highlights include:

The top five PET oncology applications are for respiratory, breast cancer, lymphoma and colorectal cancer.

Ninety-four percent of the PET patient studies used radiopharmaceuticals purchased from an outside supplier and 6 percent were obtained from cyclotrons on site.

The five states with the highest PET patient study volume are Florida, California, New York, Texas and Pennsylvania.

IMV’s 2011 PET and PET/CT Census Database provides comprehensive profiles of the identified PET imaging sites in the United States. The database can be licensed by qualified subscribers and includes contact and site-specific information. IMV's 2011 PET Imaging Market Summary Report is available with the database license, or as a separate purchase.

For more information: www.PETReport.imvinfo.com

Related Content

Researchers Trace Parkinson's Damage in the Heart
News | PET Imaging | July 17, 2018
A new way to examine stress and inflammation in the heart will help Parkinson’s researchers test new therapies and...
Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017
Blood clots in veins and arteries can lead to heart attack, stroke and pulmonary embolism, which are major causes of...
PET imaging, atherosclerotic plaque, inflammation, Ga-68-pentixafor, Technishe Universitat Munchen, Germany

Note the high uptake of Ga-68-pentixafor on multi-planar reconstructions in the organs expressing CXCR4 such as the spleen (red arrows) and adrenal glands (yellow arrows), which was nearly completely blocked by the pre-injection of AMD 3100, a potent CXCR4 inhibitor. Strong accumulation of Ga-68-pentixafor was also found in the kidneys (asterisks) reflecting the renal clearance of the tracer. In addition, high, focal activities were detected in the abdominal aorta (red arrowheads) and right carotid artery (orange arrowheads) of atherosclerotic rabbits, whereas no significant signal could be detected in the non-injured left carotid artery (white arrowheads) of atherosclerotic and control rabbits, as well as in the abdominal aorta and right carotid artery of control rabbits. Furthermore, focal activities detected with PET in atherosclerotic plaques of the abdominal aorta and the right carotid artery decreased significantly when the same rabbit was re-imaged after blocking CXCR4 receptors. Image courtesy of Fabien Hyafil, M.D., Ph.D., Department of Nuclear Medicine, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany

News | PET Imaging | March 03, 2017
In the featured article of the March 2017 issue of The Journal of Nuclear Medicine, researchers demonstrate that a new...
ASNC, SNMMI, position statement, myocardial perfusion PET, coronary artery disease
News | PET Imaging | September 01, 2016
September 1, 2016 — The American Society for Nuclear Cardiology (ASNC) and the Society of...
cardiac PET, myocardial perfusion, PET-CT, cardiac perfusion

A PET-CT cardiac perfusion exam from a Siemens Biograph scanner. The black and white areas of the image show the CT imaging of the anatomy. The colored portion shows the PET overlay on the myocardium and is color-coded to show tracer uptake values. This can show areas of the heart muscle where there are perfusion defects cause by infarcts or coronary artery blockages due to a heart attack and help determine the severity of the ischemia.

Feature | PET Imaging | June 03, 2016 | Dave Fornell
Positron emission tomography (PET) is a nuclear imaging technology (also referred to as molecular imaging) that enabl
blood clot detection, single scan, rats, radionuclides, Peter Caravan, whole body

The whole body of a rat can be imaged for blood clots with one PET scan (which is overlaid here on an MRI image) using the FBP8 probe. Arrow points to a blood clot. Image courtesy of Peter Caravan, Ph.D.

News | PET Imaging | September 23, 2015
September 23, 2015 — New research de
Overlay Init